Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to soothe ICU delirium and prevent breathing tubes

NCT ID NCT07377981

Not yet recruiting Symptom relief Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests whether a combination of two sedatives, esketamine and dexmedetomidine, can better control agitation and shorten delirium in intensive care unit (ICU) patients who are on non-invasive breathing support. The trial will enroll 388 adults with hyperactive delirium and compare the drug combo to standard care. The goal is to see if this approach reduces the need for breathing tubes and speeds recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
esketamine combined with dexmedetomidine
What this could lead to
If it works, this could offer a safer, more effective way to manage severe agitation and delirium in ICU patients, potentially reducing the need for breathing tubes.
What could go wrong
This is a single-blind, phase 4 trial with 388 participants, so results may not apply to all ICU patients. The drug combo may cause side effects like sedation or breathing problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia pain agnosia Psychomotor Agitation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGITATION ANALGESIA DEXMEDETOMIDINE INTENSIVE CARE UNITS (ICUS) KETAMINE RESPIRATORY THERAPY SEDATION AND ANALGESIA

Contacts and locations

Locations

  • The First Affiliated Hospital with Nanjing Medical University

    Nanjing, Jiangsu, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.